U.S. Compounding Pharmacy Companies, Business & Management Outlook

Top Companies in the U.S. Compounding Pharmacy Market

• PCCA (Professional Compounding Centers of America)
• B. Braun Medical Inc.
• Medisca Inc.
• Fagron Inc
• Wedgewood Pharmacy
• Avella Specialty Pharmacy
• NuVision Pharmacy
• Diamond Pharmacy
• Belmar Pharmacy
• The Compounding Pharmacy of America
• RXCrossroads (McKesson)
• PharMEDium (Fresenius Kabi)
• Central Pharmacy
• CustomMed Pharmacy
• BioMatrix Specialty Pharmacy
• Epic Pharmacy
• HealthLink Compounding Pharmacy
• National Pharmaceutical Services (NPS)
• Kane Compounding Pharmacy
• Sage Specialty Pharmacy

Market Growth

The global U.S. compounding pharmacy market size in 2024 was US$ 6.57 billion, expected to grow to US$ 6.98 billion in 2025 and further to US$ 12.02 billion by 2034, backed by a robust CAGR of 6.24% between 2025 and 2034.

Value Chain Analysis

Research & Development (R&D)

Focus on developing novel formulations, delivery systems, and bioidentical therapies tailored to patient needs. Activities include stability studies, safety profiling, and compatibility testing of active pharmaceutical ingredients (APIs).

Organizations: Compounding pharmacies’ in-house R&D units, academic research centers, pharmaceutical ingredient suppliers, and technology partners working on automated compounding systems.

Clinical Trial and Approval

While compounded drugs are not FDA-approved like commercial drugs, they must comply with USP standards (USP <795>, <797>, <800>) and FDA oversight for 503A and 503B pharmacies. Quality assurance involves sterility testing, batch testing, and adherence to Current Good Manufacturing Practices (CGMP) in outsourcing facilities.

Organizations: U.S. Food and Drug Administration (FDA), United States Pharmacopeia (USP), state pharmacy boards, and 503B outsourcing facilities.

Patient Support and Service

Services include customized dosage adjustments, allergen-free formulations, telehealth consultations, and direct-to-patient or hospital delivery. Pharmacies provide ongoing patient education, refill reminders, therapy monitoring, and adverse event reporting to ensure safety and adherence.

Organizations: Compounding pharmacies (503A and 503B), hospitals, specialty clinics, telehealth providers, and patient advocacy groups supporting awareness of personalized therapies.

Latest Announcement by Industry Leaders

In May 2025, the Chairman and CEO of LifeMD, stated that LifeMD, Inc., a leading virtual primary care provider has announced a special US$299 introductory bundle for new self-pay patients who are prescribed Wegovy (semaglutide). This bundle includes both the prescription drugs and the ability to use LifeMD's online weight-loss program. In light of April, LifeMD announced a partnership with Novo Nordisk to offer Wegovy at a discounted price of US$199. An extra US$100 will cover LifeMD's clinical care, onboarding, and maintenance.

Recent Development in the U.S. Compounding Pharmacy Market

• In February 2025, according to Eli Lilly and Company, Zepbound (tirzepatide) single-dose vials containing 7.5 mg and 10 mg are now available for US$499 through the new Zepbound Self Pay Journey Program. The 2.5 mg and 5 mg vials were also less expensive thanks to Lilly. LillyDirect Self Pay Pharmacy Solutions is the only way to access these new products. Eliminating third-party supply chain participants allows patients to see prices transparently and take advantage of savings without insurance.
• In September 2025, Pete Pharma and FABRX, the world leader in pharmaceutical 3D printing, announced a ground-breaking collaboration to bring this cutting-edge technology to the compounding pharmacy market in the United States. Since its founding more than ten years ago, FABRX has effectively implemented pharmaceutical 3D printing in clinical research facilities, hospitals, and academic institutions all over the world. Pete Pharma will take advantage of this solid base of scientific verification to develop a commercially feasible, pharmaceutically ready solution for the first time in the US.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com